KUALA LUMPUR, April 9 -- Symphony Health, a PRA Health Sciences company, will make a 30-day licence of its newly-released Metys™ COVID-19 Module available to the United States (US) life sciences industry, for free.
According to a statement, the COVID-19 Module will provide up to three users per company with access to all drugs and markets within any US geographic region down to the core-based statistical area.
The module will include history back to October 2018 to ensure access to comparative flu season trends in prior years, with March 2020 data becoming available on April 10.
Companies may publish or report insights or findings from the data with prior permission from Symphony.
Powered by Symphony’s IDV® (Integrated Dataverse), Metys is the first platform of its kind that delivers pharmaceutical market analytics and intelligence that is both timely and comprehensive.
Metys is a web-based tool that intelligently integrates prescription, payer and anonymised patient data via one single access point — all while delivering insights faster than any other tool in the industry.
Metys accesses over 60 terabytes of automatically included weekly and monthly data, reflecting the breadth of data and advancements in machine learning.
Symphony Health president, Doug Fulling said: “As we mobilise to fight COVID-19, those in life sciences can use the data and insights available to see trends, to react quickly and then plan for the future.”
“We are hoping this level of insight from one of the most robust databases in the US market benefits not only our clients and their patients, but also society as a whole.”
-- BERNAMA
No comments:
Post a Comment